01/05/2025 – AB Science today announced that it has postponed the publication of its 2024 annual financial report, initially scheduled for 30 April 2025, to give the auditors time to complete their audit work Download PDF Post navigationPreviousPrevious post:European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaNextNext post:AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingRelated PostsAB Science announces the successful completion of a EUR 1.8 million private placementMay 20, 2025AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025AB Science reports a new publication in the scientific journal PLOS OneMay 15, 2025CNews – Interview of Alain MoussyMay 12, 2025Annual financial results as of 31 December, 2024May 12, 2025AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingMay 5, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
AB Science will present new data from masitinib clinical program in ALS in two presentations at the 2025 ENCALS Annual MeetingMay 5, 2025
